Boehringer bags CHMP backing for Ofev in rare lung diseaseBoehringer Ingelheim has moved a step closer to getting approval for its blockbuster respiratory drug Ofev as the Share XBoehringer bags CHMP backing for Ofev in rare lung diseasehttps://pharmaphorum.com/news/boehringer-bags-chmp-backing-for-ofev-in-rare-lung-disease/
Jazz targets US launch of SCLC drug after FDA grants fast reviewPharmaMar and Jazz Pharmaceuticals have announced the FDA has granted a six-month Priority Review for their lurbinectedin for Share XJazz targets US launch of SCLC drug after FDA grants fast reviewhttps://pharmaphorum.com/news/jazz-targets-us-launch-of-sclc-drug-after-fda-grants-fast-review/
PharmaMar and Jazz sign $1bn US deal for lung cancer drug lurbinectedinSpain’s PharmaMar and Jazz Pharmaceuticals have signed a $1 billion license agreement for the lung cancer drug lurbinectedin Share XPharmaMar and Jazz sign $1bn US deal for lung cancer drug lurbinectedinhttps://pharmaphorum.com/news/pharmamar-and-jazz-sign-1bn-us-deal-for-lung-cancer-drug/
